Alkermes (ALKS)

• Market cap: $4.45B
• 1 day: 0.00%
• 5 days: -0.74%
• 1 month: -21.97%
• 3 months: -10.30%
• 6 months: -2.56%
• Year to date: -6.09%
• 1 year: 12.17%
• 5 years: 66.36%
• 10 years: -57.03%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 1,800

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

133% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 7 (+4) [Q4]

72% more call options, than puts

Call options by funds: $7.15M | Put options by funds: $4.15M

23% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 44

1% more funds holding

Funds holding: 334 [Q3] → 338 (+4) [Q4]

3% less capital invested

Capital invested by funds: $4.94B [Q3] → $4.81B (-$136M) [Q4]

9% less repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 126

8.48% less ownership

Funds ownership: 107.29% [Q3] → 98.81% (-8.48%) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $32 19% upside
• Avg. target: $43 57% upside
• High target: $52 93% upside

4 analyst ratings

• positive: 2 50%
• neutral: 2 50%
• negative: 0 0%

Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target	93% upside $52	Buy Maintained	27 Mar 2025
RBC Capital Leonid Timashev 12% 1-year accuracy 5 / 42 met price target	48% upside $40	Sector Perform Initiated	13 Mar 2025
Goldman Sachs Chris Shibutani 25% 1-year accuracy 3 / 12 met price target	19% upside $32	Buy Maintained	14 Feb 2025
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 30 / 172 met price target	70% upside $46	Neutral Reiterated	13 Feb 2025